The Utility of Procalcitonin as a Biomarker to Limit the Duration of Antibiotic Therapy in Adult Sepsis Patients
Sepsis is a potentially life-threatening
complication of an infection. Sepsis occurs when chemicals released into the
bloodstream to fight the infection trigger inflammatory responses throughout
the body. In the modern antibiotic era, treatment protocols for sepsis
necessitate the rapid institution of broad-spectrum antibiotics.
Pocalcitonin (PCT)
is a biomarker with unique properties that make it a potential serum marker for
directing the clinical management of sepsis. A growing literature on
procalcitonin suggests significant potential for its use in the diagnosis of
sepsis, although its role in clinical medicine continues to be controversial. This
report sought to evaluate the evidence-based data available from prospective
randomized controlled trials (RCT) on the role of PCT in guiding reductions in
antibiotic duration in adult sepsis patients.
A comprehensive
search of published prospective RCT(s) on the use of PCT as a tool for guiding
antibiotic therapy in adult sepsis patients was conducted using PubMed, Medline
Plus and Google Scholar (2007-2013). Keywords searched included,
“procalcitonin”, “sepsis-therapy”, “sepsis biomarker”, “antibiotic duration”,
“drug de-escalation”, and “antimicrobial stewardship”. Finally, four prospective randomized studies evaluating the utility of PCT
serums levels in reducing antibiotic duration have been found, of which all
report beneficial outcomes. All four studies utilized a similar design, in
which a “PCT-directed intervention arm” was compared with a “standard of care
arm”. And the studies shared several common endpoints, specifically the
reduction of antibiotic therapy duration (in days) and patient mortality,
though each study utilized different criteria in determining the optimal
timeframe for antibiotic discontinuation.
In summary,
PCT-guided early cessation of antibiotic therapy in adult sepsis patients is
associated with a significant decrease in antibiotic days, without any change
in overall mortality. Given the success of these trials, PCT may find a place
in antimicrobial stewardship programs aimed at limiting antibiotic therapy
duration while decelerating the development of antibiotic resistance.
Article by Ronald
S. Chamberlain, et al, from USA and West Indies.
Full access: http://suo.im/4ZY1gk
评论
发表评论